InterCure advances restoration of Israeli site amid conflict By Investing.com
[ad_1]
© Reuters
NEW YORK, and HERZLIYA, Israel – InterCure Ltd. (NASDAQ: INCR) (TASE: INCR), a prominent medical cannabis company, announced ongoing restoration efforts at its Southern Israel Site, which has faced limited access since the war situation declared on October 7, 2023. The company, also known as Canndoc, is in the process of repairing the facility, which has been partially used by the Israeli Defense Forces, including the medical corps.
The company expressed confidence in receiving full compensation from the Israeli government for direct and indirect damages sustained during the conflict, as previously mentioned in their October 17, 2023, press release. InterCure is also dedicated to supporting patient communities affected by the situation, particularly those in evacuated areas, as well as casualties and IDF veterans.
InterCure, which holds a leadership position in Israel’s medical cannabis market, is committed to not only restoring but further developing the site at Kibbutz Nir-Oz. They have expressed gratitude towards their managers, employees, and strategic partners for their support during these challenging times.
The company plans to file preliminary results for the second half of 2023 and the full year of 2023 in early March, with a complete financial report for 2023 expected in April.
InterCure operates as a vertically integrated company, from seed-to-sale, and is recognized for its distribution network and international partnerships.
It is considered the leading profitable and fastest-growing cannabis company outside North America. Canndoc, its subsidiary, is a major licensed cannabis producer in Israel and offers pharmaceutical-grade medical cannabis products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters
NEW YORK, and HERZLIYA, Israel – InterCure Ltd. (NASDAQ: INCR) (TASE: INCR), a prominent medical cannabis company, announced ongoing restoration efforts at its Southern Israel Site, which has faced limited access since the war situation declared on October 7, 2023. The company, also known as Canndoc, is in the process of repairing the facility, which has been partially used by the Israeli Defense Forces, including the medical corps.
The company expressed confidence in receiving full compensation from the Israeli government for direct and indirect damages sustained during the conflict, as previously mentioned in their October 17, 2023, press release. InterCure is also dedicated to supporting patient communities affected by the situation, particularly those in evacuated areas, as well as casualties and IDF veterans.
InterCure, which holds a leadership position in Israel’s medical cannabis market, is committed to not only restoring but further developing the site at Kibbutz Nir-Oz. They have expressed gratitude towards their managers, employees, and strategic partners for their support during these challenging times.
The company plans to file preliminary results for the second half of 2023 and the full year of 2023 in early March, with a complete financial report for 2023 expected in April.
InterCure operates as a vertically integrated company, from seed-to-sale, and is recognized for its distribution network and international partnerships.
It is considered the leading profitable and fastest-growing cannabis company outside North America. Canndoc, its subsidiary, is a major licensed cannabis producer in Israel and offers pharmaceutical-grade medical cannabis products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
